CSI 2016 ESC

Episodes 1-10 of 10

Careful implementation of PCSK9 inhibitors in clinical practice
Careful implementation of PCSK9 inhibitors in clinical practice
CSI 2016 ESC
Careful implementation of PCSK9 inhibitors in clinical practice
- Prof. dr. Terje Pedersen
Possible approaches in precision medicine for secundary CV prevention
Possible approaches in precision medicine for secundary CV prevention
CSI 2016 ESC
Possible approaches in precision medicine for secundary CV prevention
- Dr. Noel Bairey Merz
To SPRINT or not to SPRINT to a lower blood pressure target?
To SPRINT or not to SPRINT to a lower blood pressure target?
CSI 2016 ESC
To SPRINT or not to SPRINT to a lower blood pressure target?
What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?
What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?
CSI 2016 ESC
What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?
- Prof. Silvio E Inzucchi
A minority of FH patients is identified and labeled as such, which impacts treatment
A minority of FH patients is identified and labeled as such, which impacts treatment
CSI 2016 ESC
A minority of FH patients is identified and labeled as such, which impacts treatment
- Prof Kausik Ray
Interim results of new device for treatment resistant hypertension
Interim results of new device for treatment resistant hypertension
CSI 2016 ESC
Interim results of new device for treatment resistant hypertension
- Dr. Wilko Spiering
Would lower than the current ApoB targets be more useful for clinical decision-making?
Would lower than the current ApoB targets be more useful for clinical decision-making?
CSI 2016 ESC
Would lower than the current ApoB targets be more useful for clinical decision-making?
- Seth Shay Martin, MD
Targeting residual inflammatory risk as a strategy to lower CV risk
Targeting residual inflammatory risk as a strategy to lower CV risk
CSI 2016 ESC
Targeting residual inflammatory risk as a strategy to lower CV risk
- prof. Paul Ridker, MD
Understanding why patients do not take their medication and stimulating adherence
Understanding why patients do not take their medication and stimulating adherence
CSI 2016 ESC
Understanding why patients do not take their medication and stimulating adherence
- Prof. Robert Horne
Bisphosphonate as a potential new treatment for CV risk reduction
Bisphosphonate as a potential new treatment for CV risk reduction
CSI 2016 ESC
Bisphosphonate as a potential new treatment for CV risk reduction

Episodes 1-10 of 10

Title

Share on ReachMD